18775-43-4

Usage

Physical state

Colorless to light yellow liquid

Odor

Faint

Uses

Intermediate in the synthesis of pharmaceuticals and organic compounds; potential use in medicinal chemistry for creating new drugs and biologically active molecules

Versatility

Used as a reagent in organic chemistry reactions, making it a valuable tool for chemical synthesis and research.

Upstream product

• 18775-42-3 5-chloromethylindane 
• 143-33-9 sodium cyanide 
• 151-50-8 potassium cyanide 
• 65898-38-6 indan-5-carboxylic acid 
• 51632-06-5 (2,3-dihydro-1H-inden-5-yl)methanol 
• 4228-10-8 1-indan-5-yl-ethanone 
• 7732-18-5 water 
• 496-11-7 INDANE 

Relevant academic research and scientific papers

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides

A series of substituted 3H-1,2,3,5-oxathiadiazole-2-oxides (6) was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. The oxathiadiazoles 6 were synthesized by a two-step sequence: treatment of a substituted acetonitrile (4) with hydroxylamine to give the corresponding amidoxime (5) and cyclization with thionyl chloride to yield 6. In terms of potency, the 2-naphthalenylmethyl group (as in compound 3) was found to be the optimal substituent in this series. Compound 3 was approximately 5 times more potent than ciglitazone (1).

Novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides useful as anthihyperglycemic agents

This invention relates to novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides, to the processes for their preparation, to methods for using the compounds, and to pharmaceutical compositions thereof. The compounds have pharmaceutical properties which render them beneficial for the treatment of diabetes mellitus and associated conditions.